Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pan-cancer whole-genome analyses of metastatic solid tumours.
Priestley P, Baber J, Lolkema MP, Steeghs N, de Bruijn E, Shale C, Duyvesteyn K, Haidari S, van Hoeck A, Onstenk W, Roepman P, Voda M, Bloemendal HJ, Tjan-Heijnen VCG, van Herpen CML, Labots M, Witteveen PO, Smit EF, Sleijfer S, Voest EE, Cuppen E. Priestley P, et al. Among authors: van hoeck a, van herpen cml. Nature. 2019 Nov;575(7781):210-216. doi: 10.1038/s41586-019-1689-y. Epub 2019 Oct 23. Nature. 2019. PMID: 31645765 Free PMC article.
Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.
van Cruijsen H, Voest EE, Punt CJ, Hoekman K, Witteveen PO, Meijerink MR, Puchalski TA, Robertson J, Saunders O, Jürgensmeier JM, van Herpen CM, Giaccone G. van Cruijsen H, et al. Eur J Cancer. 2010 Mar;46(5):901-11. doi: 10.1016/j.ejca.2009.12.023. Epub 2010 Jan 12. Eur J Cancer. 2010. PMID: 20061136 Clinical Trial.
Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.
Plummer R, Swaisland H, Leunen K, van Herpen CM, Jerusalem G, De Grève J, Lolkema MP, Soetekouw P, Mau-Sørensen M, Nielsen D, Spicer J, Fielding A, So K, Bannister W, Molife LR. Plummer R, et al. Cancer Chemother Pharmacol. 2015 Oct;76(4):723-9. doi: 10.1007/s00280-015-2836-2. Epub 2015 Aug 5. Cancer Chemother Pharmacol. 2015. PMID: 26242220 Clinical Trial.
Molecular Tumor Boards: current practice and future needs.
van der Velden DL, van Herpen CML, van Laarhoven HWM, Smit EF, Groen HJM, Willems SM, Nederlof PM, Langenberg MHG, Cuppen E, Sleijfer S, Steeghs N, Voest EE. van der Velden DL, et al. Among authors: van laarhoven hwm, van herpen cml. Ann Oncol. 2017 Dec 1;28(12):3070-3075. doi: 10.1093/annonc/mdx528. Ann Oncol. 2017. PMID: 29045504 Free article.
Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients.
Bins S, Huitema ADR, Laven P, Bouazzaoui SE, Yu H, van Erp N, van Herpen C, Hamberg P, Gelderblom H, Steeghs N, Sleijfer S, van Schaik RHN, Mathijssen RHJ, Koolen SLW. Bins S, et al. Clin Pharmacokinet. 2019 May;58(5):651-658. doi: 10.1007/s40262-018-0719-5. Clin Pharmacokinet. 2019. PMID: 30367352 Free PMC article. Clinical Trial.
Molecular tumour boards and molecular diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations.
Willemsen AECAB, Krausz S, Ligtenberg MJL, Grünberg K, Groen HJM, Voest EE, Cuppen EPJG, van Laarhoven HWM, van Herpen CML. Willemsen AECAB, et al. Among authors: van laarhoven hwm, van herpen cml. Br J Cancer. 2019 Jul;121(1):34-36. doi: 10.1038/s41416-019-0489-3. Epub 2019 May 27. Br J Cancer. 2019. PMID: 31130724 Free PMC article.
RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.
van Helden EJ, Angus L, Menke-van der Houven van Oordt CW, Heideman DAM, Boon E, van Es SC, Radema SA, van Herpen CML, de Groot DJA, de Vries EGE, Jansen MPHM, Sleijfer S, Verheul HMW. van Helden EJ, et al. Among authors: van herpen cml, van es sc. Mol Oncol. 2019 Nov;13(11):2361-2374. doi: 10.1002/1878-0261.12550. Epub 2019 Sep 30. Mol Oncol. 2019. PMID: 31350822 Free PMC article.
252 results